LSV Asset Management Purchases New Stake in Illumina, Inc. $ILMN

LSV Asset Management acquired a new position in shares of Illumina, Inc. (NASDAQ:ILMN) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 20,400 shares of the life sciences company’s stock, valued at approximately $1,937,000.

Other large investors have also recently made changes to their positions in the company. Parkside Financial Bank & Trust increased its position in shares of Illumina by 65.7% during the second quarter. Parkside Financial Bank & Trust now owns 290 shares of the life sciences company’s stock worth $28,000 after acquiring an additional 115 shares in the last quarter. Quent Capital LLC acquired a new position in Illumina during the 3rd quarter valued at about $29,000. Cullen Frost Bankers Inc. bought a new stake in Illumina during the 2nd quarter worth approximately $41,000. NewSquare Capital LLC raised its stake in shares of Illumina by 604.9% in the second quarter. NewSquare Capital LLC now owns 430 shares of the life sciences company’s stock worth $41,000 after purchasing an additional 369 shares during the last quarter. Finally, Mather Group LLC. bought a new position in shares of Illumina in the third quarter valued at approximately $46,000. 89.42% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several brokerages recently issued reports on ILMN. Evercore ISI set a $150.00 price target on Illumina in a report on Friday, February 6th. Robert W. Baird set a $137.00 target price on shares of Illumina in a research note on Friday, February 6th. Evercore set a $150.00 price target on shares of Illumina in a research report on Friday, February 6th. Piper Sandler cut their price target on shares of Illumina from $195.00 to $170.00 and set an “overweight” rating on the stock in a report on Monday, February 9th. Finally, Barclays increased their price objective on shares of Illumina from $100.00 to $110.00 and gave the company an “underweight” rating in a research note on Monday, December 15th. Six research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $129.17.

Illumina Trading Up 2.1%

Shares of ILMN stock opened at $116.81 on Tuesday. The company has a quick ratio of 1.72, a current ratio of 2.08 and a debt-to-equity ratio of 0.55. The firm has a market cap of $17.86 billion, a P/E ratio of 21.43, a PEG ratio of 2.23 and a beta of 1.45. The company has a 50 day moving average of $137.08 and a 200-day moving average of $116.74. Illumina, Inc. has a 12-month low of $68.70 and a 12-month high of $155.53.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Thursday, February 5th. The life sciences company reported $1.35 EPS for the quarter, beating the consensus estimate of $1.26 by $0.09. Illumina had a return on equity of 31.04% and a net margin of 19.57%.The business had revenue of $1.16 billion for the quarter, compared to the consensus estimate of $1.10 billion. During the same quarter in the prior year, the business earned $0.95 earnings per share. Illumina’s revenue for the quarter was up 5.0% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.050-5.200 EPS. Sell-side analysts anticipate that Illumina, Inc. will post 4.51 earnings per share for the current year.

Insiders Place Their Bets

In other Illumina news, insider Scott M. Davies sold 323 shares of the company’s stock in a transaction dated Friday, December 12th. The shares were sold at an average price of $136.09, for a total transaction of $43,957.07. Following the sale, the insider directly owned 17,887 shares of the company’s stock, valued at $2,434,241.83. This represents a 1.77% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Company insiders own 0.17% of the company’s stock.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.